Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 9,000 shares of common stock at $16.54 per share and sold 9,000 shares at a weighted average price of $117.94 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance. After the transactions, he directly owns 7,825 shares of common stock.
PTGX affiliate filed Form 144 reporting proposed and recent sales of Common Stock. The filing lists a proposed sale of 9,000 shares on 06/23/2026 described as an Exercise of Stock Options for cash. It also records 10b5-1 sales of 9,000 shares on 06/10/2026 for $969,152.40 and 9,000 shares on 05/29/2026 for $896,730.30.
Protagonist Therapeutics, Inc. held its 2026 annual stockholder meeting, with 64,305,185 common shares entitled to vote. Stockholders approved a new 2026 Equity Incentive Plan, which replaces the 2016 plan and allows future awards using remaining 2016 plan shares plus 650,000 new shares and certain returning shares.
Two Class I directors, Dinesh V. Patel and Lewis T. “Rusty” Williams, were re-elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Protagonist Therapeutics director William D. Waddill exercised stock options for 9,000 shares of common stock at strike prices of $16.54 and $11.80, then sold 9,000 shares in an open-market transaction at a weighted average price of $107.68 under a pre-arranged Rule 10b5-1 trading plan, leaving him with 7,825 shares held directly.
PTGX-related transaction notice: A broker-dealer submission lists the proposed sale and related exercise of 9,000 shares. The filing records a 10b5-1 sale of 9,000 shares on 05/29/2026 producing $896,730.30 and an exercise of stock options for 9,000 shares on 06/10/2026 with cash payment.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction. He exercised 9,000 shares of Common Stock at $11.80 per share, then sold 9,000 shares in an open-market sale at $99.64 per share.
After these transactions, he directly holds 7,825 shares of Common Stock and 3,000 stock options remain outstanding, with the options expiring on June 6, 2029. The filing notes the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock. On May 12, 2026, he exercised stock options for 75,000 shares at $21.58 per share and sold 75,000 shares in open-market trades at a weighted average price of $100.12 per share, with individual sale prices ranging from $98.83 to $103.50. After these transactions, he directly holds 523,478 common shares. The filing notes the actions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026, and that the related stock options are fully vested and expire on October 11, 2026, with 225,000 options reported as remaining outstanding.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 75,000 shares of common stock at an exercise price of $21.58 per share, then sold 75,000 shares in an open-market transaction at a weighted average price of $100.12 per share across multiple trades ranging from $98.83 to $103.50. Following these transactions, he directly holds 523,478 shares of common stock. The exercised stock options were fully vested and are scheduled to expire on October 11, 2026.
PTGX insider sale notice: A Form 144 filing states 75,000 shares of Common Stock are to be sold on 05/12/2026 in connection with an Option Exercise for cash. The filing also reports prior sales of 54,641 shares on 03/25/2026 by Dinesh Patel.